Background
==========

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor in the gastrointestinal tract and are often characterized by cellular markers, such as CD117 (a c-kit gene proto-oncogene product) and CD34 (a human progenitor cell antigen) \[[@B1]-[@B3]\]. GISTs, which frequently occur in the stomach and small intestine \[[@B2]\], have malignant potential, and recurrence of GISTs often occurs at the peritoneal surface or liver \[[@B4]\]. Targeted therapies have been developed for GISTs, but surgical resection remains the optimal initial treatment approach for primary GISTs with no evidence of metastasis. The surgical principles of gastrointestinal stromal tumor comprise *en bloc* resection (R0 resection) with avoidance of rupture, which may result in peritoneal seeding. In addition, lymphadenectomy is not indicated in GISTs because of a very low propensity for lymph node metastases \[[@B5]\].

With the development of minimally invasive surgical approaches, laparoscopic surgery (LAP) for gastrointestinal stromal tumors has evolved rapidly over the past decades. Various types of laparoscopic approaches for GISTs have been performed in a few specialized centers, including wedge resection of the stomach, intragastric tumor resection, and combined endoscopic-laparoscopic resection \[[@B6]-[@B9]\]. Owing to the technique difficulty and relative rarity of GISTs, there is few study of large scale of patients reporting the short- and long-term results for LAP for GISTs compared with open surgery (OPEN). To address these issues, our team conducted the following meta-analysis to compare short-term and long-term results of patients undergoing LAP.

Methods
=======

Search strategy
---------------

A systematic search was conducted in PubMed, Embase, Cochrane Library, and Web of Science to identify articles published up to June 2014. The search terms included 'gastrointestinal stromal tumor', 'GIST', 'laparoscop\*', 'gastrectomy' and "gastric resection'. A personal search was also performed with reference lists of the retrieved relevant articles and reviews to identify additional trials and ensure that all the potential studies were included. The language of the articles was limited to English and Chinese according to the reviewers' language competence.

Study selection
---------------

The inclusion criteria were as follows: comparative, peer-reviewed studies of LAP versus OPEN for GISTs for which the full text of the article was available. If two or more studies from the same institution, the most recent study or that including informative data was selected unless the reports were from different time periods. We excluded studies including: GISTs out of the stomach; complicated with mixed disease, such as gastric cancer; studies in which fewer than two relevant indexes were reported, or where it was difficult to calculate these from the results; and studies where the measured outcomes were not clearly presented in the literature.

Data extraction and quality assessment
--------------------------------------

Two researchers independently extracted the data and disagreement was resolved through discussion. Extracted data included author, study period, geographical region, number of patients, operation time, blood loss, time to flatus, time to oral intake, length of hospital stay, morbidity, mortality, and long-term outcomes. The Newcastle-Ottawa Quality Assessment Scale (NOS) was used as an assessment tool. This scale varies from zero to nine stars: studies with a score equal to or higher than six were considered methodologically sound.

Outcome definition and Statistical analysis
-------------------------------------------

Postoperative complications were classified as systematic complications (cardiovascular, respiratory or metabolic events; nonsurgical infections; deep venous thrombosis; and pulmonary embolism) or surgical complications (any anastomotic leakage or fistula, any complication that required reoperation, intra-abdominal collections, wound complications, bleeding events, pancreatitis, ileus, delayed gastric emptying, and anastomotic stricture). This classification system is based on the Memorial Sloan-Kettering Cancer Center complication reporting system \[[@B10]\]. Continuous variables were assessed using weighted mean difference (WMD), and dichotomous variables were analyzed using the risk ratio (RR). If the study provided medians and ranges instead of means and standard deviations, we estimated the means and standard deviations as described by Hozo *et al*. \[[@B11]\]. Statistical heterogeneity was evaluated by the Higgins *I*^2^ statistic \[[@B12]\]. Based on method reported by DerSimonian and Laird \[[@B13]\], substantial significance was set when P \< 0.10 and a random effect model was used. We hypothesized the outcomes of the comparison may be affected by the uneven distribution of the surgical types between the LAP and OPEN groups, especially by the relatively larger proportion of extended surgeries performed in the OPEN group. Thus, we performed a subgroup analysis of patients who underwent wedge resection in the two groups to eliminate the bias from the surgical type selection. We also conducted a subgroup analysis of studies that had comparable tumor size or risk index proposed by Fletcher *et al*. \[[@B3]\], which may have an impact on the operative outcomes. The potential publication bias based on the postoperative complications was assessed Begg's test and funnel plots. Data analyses were performed using STATA (version 12.0). *P* \<0.05 was considered statistically significant.

Results
=======

Studies selected
----------------

By the initial search, 768 potentially relevant articles were identified. After the titles and abstracts were reviewed, papers without comparison of LAP and OPEN were excluded, which left 28 comparative studies. An additional six \[[@B14]-[@B19]\] studies did not meet the inclusion criteria and were excluded. In total, 22 observational studies were obtained \[[@B20]-[@B41]\], all of which were accessible in full-text format. Twenty-one studies were published in English and one in Chinese. A flow chart of the search strategies, which contains reasons for exclusion, is presented in Figure [1](#F1){ref-type="fig"}.

![**Flow chart of literature search strategies.** GIST, gastrointestinal stromal tumor.](1477-7819-12-206-1){#F1}

Characteristics and quality of studies
--------------------------------------

A total of 1,166 patients were included in the analysis with 574 undergoing LAP (49.2%) and 592 undergoing OPEN (50.8%). They represented an international experience, with data included from 10 different countries or regions (six Japan, four United States, four China, two Korea, one United Kingdom, one Italy, one Belgium, one Austria, one Singapore and one Taiwan). According to the NOS, one out of the 22 observational studies got six stars, six articles got seven stars, eight articles got eight stars and the remaining seven got nine stars. Overall, all studies were evaluated as being moderate to high quality. The characteristics and methodological quality assessment scores of the included studies are summarized in Table [1](#T1){ref-type="table"}.

###### 

Summary of studies included in the meta-analysis

  **Author**                            **Region**   **Study design**   **Year**   **Study period**   **Sample size**   **Conversion (%)**   **Follow-up (month)**   **Recurrence**        **Quality scores**               
  ------------------------------------- ------------ ------------------ ---------- ------------------ ----------------- -------------------- ----------------------- --------------------- ---------------------- ---- ---- ---
  Shimizu *et al*. \[[@B20]\]           Japan        OCS (R)            2002       1986-2000          11                8                    0                       NR                    NR                     NR   NR   7
  Matthews *et al*. \[[@B21]\]          USA          OCS (R)            2002       1994-2000          21                12                   NR                      20                    18                     1    1    7
  Ishikawa *et al*. \[[@B22]\]          Japan        OCS (R)            2006       1993-2004          14                7                    NR                      60 (5 to 119)         61 (3 to 130)          2    1    8
  Mochizuki *et al*. \[[@B23]\]         Japan        OCS (R)            2006       2000-2004          12                10                   NR                      26 (6 to 53)          NR                     0    0    8
  Nishimura *et al*. \[[@B24]\]         Japan        OCS (R)            2007       1993-2004          39                28                   2.6                     18.9 (2.6 to 96.4)    31.2 (4.4 to 121.9)    1    4    9
  Pitsinis *et al*. \[[@B25]\]          UK           OCS (P)            2007       2004-2006          6                 7                    NR                      9                     9                      0    0    6
  Catena *et al*. \[[@B26]\]            Italy        OCS (P)            2008       1995-2006          21                25                   NR                      35 (5 to 58)          91 (80 to 136)         0    1    9
  Silberhumer *et al*. \[[@B27]\]       Austria      OCS (R)            2009       1998-2006          22                41                   18.2                    30 ± 20               41 ± 31                0    4    8
  Goh *et al*. \[[@B28]\]               Singapore    OCS (R)            2010       2001-2009          14                39                   7.1                     8 (3 to 60)           21(2 to 72)            0    2    7
  Karakousis *et al*. \[[@B29]\]        USA          OCS (P)            2011       1998-2009          40                40                   22.5                    28 (0.3 to 70)        43 (0.1 to 139)        1    1    9
  Dai *et al*. \[[@B30]\]               China        OCS (R)            2011       2000-2009          18                30                   NR                      78                    64                     2    3    9
  De Vogelaere *et al*. \[[@B31]\]      Belgium      OCS (P)            2012       1997-2011          37                16                   NR                      83 (2 to 163)         71 (0.3 to 199)        0    6    8
  Melstrom *et al*. \[[@B32]\]          USA          OCS (P)            2012       1999-2008          17                29                   5.9                     32                    59                     0    4    7
  Lee *et al*. \[[@B33]\]               Korea        OCS (R)            2011       2001-2008          50                50                   2                       21.1 (0 to 64)        22.3 (0 to 93)         0    0    9
  Wan *et al*. \[[@B34]\]               China        OCS (R)            2012       2004-2011          68                88                   NR                      29 (4 to 89)          36 (4 to 90)           3    4    9
  Pucci *et al*. \[[@B35]\]             USA          OCS (P)            2012       2002-2012          57                47                   1.8                     NR                    NR                     NR        7
  Kim *et al*. \[[@B36]\]               Korea        OCS (R)            2012       1998-2011          24                14                   NR                      62.6 (8.9 to 164.4)   58.3 (18.8 to 123.2)   1    3    7
  Shu *et al*. \[[@B37]\]               China        OCS (R)            2013       2010-2012          15                21                   NR                      NR                    NR                     N    NR   8
  Lee *et al*. \[[@B38]\]               Taiwan       OCS (R)            2013       2007-2009          30                32                   NR                      NR                    NR                     NR   NR   8
  Kasetsermwiriya *et al*. \[[@B39]\]   Japan        OCS (R)            2014       1988-2011          23                10                   NR                      46 (2 to 168)         19 (1 to 275)          0    1    8
  Lin *et al*. \[[@B40]\]               China        OCS (R)            2014       2007-2012          23                23                   4.3                     34 (6 to 78)          2                      3    9    
  Takahashi *et al*. \[[@B41]\]         Japan        OCS (R)            2014       1995-2011          12                15                   25                      57 (7 to 120)         69 (13 to 154)         1    2    8

LAP, laparoscopic surgery; NR, not reported; OCS, observational clinical study; OPEN, open surgery; P, prospectively collected data; R, retrospectively collected data.

Comparison of operative outcomes
--------------------------------

The tumor size for LAP was significantly smaller than that for OPEN (WMD = -0.98 cm; 95% CI, -1.36 to -0.60; *P* \<0.01; Figure [2](#F2){ref-type="fig"}). The present analysis showed no statistically significant difference in the operation time of the two groups (WMD = -11.22 min; 95% confidence interval (CI), -28.66 to 6.23; *P* = 0.21; Figure [3](#F3){ref-type="fig"}). Intraoperative blood loss was significantly lower in the LAP compared with the OPEN group (WMD = -58.91 ml; 95% CI, -84.60 to -33.22 ml; *P* \<0.01; Figure [4](#F4){ref-type="fig"}).

![Meta-analysis of the pooled data: tumor size (cm).](1477-7819-12-206-2){#F2}

![Meta-analysis of the pooled data: operation time (minutes).](1477-7819-12-206-3){#F3}

![Meta-analysis of the pooled data: intraoperative blood loss (ml).](1477-7819-12-206-4){#F4}

Comparison of short-term postoperative outcomes
-----------------------------------------------

The outcomes also favored LAP in first flatus day (WMD = -1.31 d; 95% CI, -1.56 to -1.06; *P* \<0.01; Figure [5](#F5){ref-type="fig"}) and first oral intake (WMD = -1.75 d; 95% CI, -2.12 to -1.39; *P* \<0.01; Figure [6](#F6){ref-type="fig"}). Moreover, postoperative hospital day was 3.68 days shorter for LAP patients (WMD = -3.68 d; 95% CI, -4.47 to -2.88; *P* \<0.01; Figure [7](#F7){ref-type="fig"}). With respect to the rate of overall postoperative complications, LAP is significantly superior to OPEN. The rate of overall postoperative complications was significantly lower for LAP (RR = 0.57; 95% CI, 0.37 to 0.89; *P* = 0.01; Figure [8](#F8){ref-type="fig"}). After further analysis, surgical complications were similar between the two groups (RR = 0.69; 95% CI, 0.37 to 1.29; *P* = 0.24). However, LAP was associated with a marginal reduction in systematic complications (RR = 0.57; 95% CI, 0.32 to 1.04; *P* = 0.07).

![Meta-analysis of the pooled data: time to first flatus (days).](1477-7819-12-206-5){#F5}

![Meta-analysis of the pooled data: time to oral intake (days).](1477-7819-12-206-6){#F6}

![Meta-analysis of the pooled data: hospital stay (days).](1477-7819-12-206-7){#F7}

![Meta-analysis of the pooled data: overall complications.](1477-7819-12-206-8){#F8}

Comparison of oncological outcomes
----------------------------------

15 studies reported tumor recurrence \[[@B21],[@B22],[@B24],[@B26]-[@B32],[@B34],[@B36],[@B39]-[@B41]\]. The recurrence risk in LAP was 3.6% (14 out of 388) and 9.7% (38 out of 393) in OPEN, and patients who underwent LAP were less likely than the OPEN group to have recurrence (RR = 0.51; 95% CI, 0.28 to 0.93; *P* = 0.03; Figure [9](#F9){ref-type="fig"}). The available data about recurrence patterns and survival outcomes are summarized in Table [2](#T2){ref-type="table"}.

![Meta-analysis of the pooled data: recurrences.](1477-7819-12-206-9){#F9}

###### 

Summary of the available data about recurrence patterns and survival outcomes

  **Case**     **Group**   **Risk**   **Recurrence**     **Survival**   **Case**     **Group**   **Risk**   **Recurrence**   **Survival**     **Case**     **Group**   **Risk**   **Recurrence**    **Survival**
  ------------ ----------- ---------- ------------------ -------------- ------------ ----------- ---------- ---------------- ---------------- ------------ ----------- ---------- ----------------- ---------------
  \[[@B21]\]   LAP         High       NR                 Dead           \[[@B26]\]   OPEN        NR         NR               Dead             \[[@B31]\]   OPEN        High       6 m Liver         52 m Alive^a^
  \[[@B21]\]   OPEN        High       NR                 14 m Dead      \[[@B27]\]   OPEN        High       Local            Dead^b^          \[[@B31]\]   OPEN        High       9 m Liver         75 m Alive^a^
  \[[@B22]\]   LAP         High       Liver              32 m Dead      \[[@B27]\]   OPEN        High       Local            Alive^a^         \[[@B31]\]   OPEN        High       21 m Liver        16y Dead^a^
  \[[@B22]\]   OPEN        High       Liver              9 m Dead       \[[@B27]\]   OPEN        High       Liver            Alive^a^         \[[@B36]\]   OPEN        High       52 m Peritoneal   Dead^a^
  \[[@B22]\]   LAP         Low        Local              Alive          \[[@B27]\]   OPEN        High       Multiple         Alive^a^         \[[@B36]\]   OPEN        High       60 m Liver        Alive
  \[[@B24]\]   LAP         Low        33 m Local         Alive          \[[@B29]\]   LAP         High       Peritoneal       4 y Alive        \[[@B36]\]   OPEN        High       6 m Colon         Dead^a^
  \[[@B24]\]   OPEN        High       7 m Peritoneal     Alive          \[[@B29]\]   OPEN        Moderate   Liver            10 y Alive       \[[@B36]\]   LAP         High       31 m Stomach      Alive
  \[[@B24]\]   OPEN        High       53 m Local         Alive          \[[@B31]\]   OPEN        High       4 m Liver        28 m Dead^a^     \[[@B36]\]   OPEN        High       15 Peritoneal     Dead^a^
  \[[@B24]\]   OPEN        High       37 m Liver         Alive          \[[@B31]\]   OPEN        High       10 m Liver       Alive^a^         \[[@B39]\]   OPEN        High       11 m Liver        59 m Alive
  \[[@B24]\]   OPEN        High       15 m Multiple^d^   Alive          \[[@B31]\]   OPEN        High       42 m Liver       46 m Dead^a,c^                                                          

LAP, laparoscopic surgery; m: month; NR, not reported; OPEN, open surgery; y: year.

^a^treated with imatinib; ^b^due to cardiac insufficiency; ^c^due to lung cancer; ^d^included liver and local recurrence.

Comparison of wedge resection
-----------------------------

Comparison data of laparoscopic wedge resection and open wedge resection was available in eight studies\[[@B20],[@B22],[@B23],[@B26],[@B28],[@B30],[@B33],[@B34]\]. The overall effects such as operation time, blood loss, time to flatus or oral intake, hospital stay, and complications remained unchanged. However, in this subgroup analysis, the recurrence risk in LAP was 5.4% (7 out of 130) and 5.5% (9 out of 165) in OPEN, and the difference was not significant (RR = 1.01; 95% CI, 0.39 to 2.63; *P* = 0.99). The outcomes of subgroup analysis for studies of wedge resection are summarized in Table [3](#T3){ref-type="table"}.

###### 

Pooled outcomes of subgroup analysis for studies of wedge resection

  **Outcomes**               **Number of studies**   **Sample size**   **Heterogeneity (*P, I***^***2***^**)**   **Overall effect size**   **95%CI of overall effect**   ***P***          
  -------------------------- ----------------------- ----------------- ----------------------------------------- ------------------------- ----------------------------- ---------------- --------
  Operation time (min)       8                       203               233                                       \<0.001, 82%              WMD = 12.03                   -8.03, 32.09     0.24
  Blood loss (ml)            5                       118               151                                       0.03, 64%                 WMD = -48.29                  -78.23, -18.36   \<0.01
  Time to first flatus (d)   6                       119               144                                       0.10, 46%                 WMD = -1.35                   -1.66, -1.03     \<0.01
  Time to oral intake (d)    7                       182               208                                       0.001, 73%                WMD = -1.67                   -2.19, -1.15     \<0.01
  Hospital stay (d)          8                       203               233                                       0.002, 68%                WMD = -2.53                   -3.50, -1.57     \<0.01
  Overall complications      8                       203               233                                       0.70, 0%                  RR = 0.47                     0.22, 1.01       0.05
  Tumor size (cm)            8                       203               233                                       0.10, 42%                 WMD = -0.77                   -1.23, -0.31     \<0.01
  Recurrence                 5                       130               165                                       0.95, 0%                  RR = 1.01                     0.39, 2.63       0.99

CI, confidence interval; LAP, laparoscopic surgery; OPEN, open surgery; RR, risk ratio; WMD, weighted mean difference.

Subgroup analysis for studies with comparable tumor size or risk index
----------------------------------------------------------------------

Thirteen studies qualified for a subgroup analysis for studies with comparable tumor size or risk index \[[@B20],[@B21],[@B23],[@B24],[@B26],[@B29],[@B30],[@B33],[@B34],[@B37]-[@B40]\]. Like the subgroup analysis for wedge resection, outcomes other than tumor recurrence remained unchanged. The recurrence risk was similar between LAP and OPEN (RR = 0.66; 95% CI, 0.31 to 1.42; *P* = 0.29). The outcomes of subgroup analysis for studies with comparable tumor size or risk index are summarized in Table [4](#T4){ref-type="table"}.

###### 

Pooled outcomes of subgroup analysis for studies with comparable tumor size or risk index

  **Outcomes**               **Number of studies**   **Sample size**   **Heterogeneity (*P, I***^***2***^**)**   **Overall effect size**   **95%CI of overall effect**   ***P***          
  -------------------------- ----------------------- ----------------- ----------------------------------------- ------------------------- ----------------------------- ---------------- --------
  Operation time (min)       13                      371               377                                       \<0.001, 81%              WMD = -1.06                   -16.93, 14.81    0.90
  Blood loss (ml)            11                      300               302                                       \<0.001, 71%              WMD = -58.20                  -81.76, -34.65   \<0.01
  Time to first flatus (d)   6                       129               142                                       0.09, 47%                 WMD = -1.28                   -1.60, -0.97     \<0.01
  Time to oral intake (d)    7                       212               241                                       0.02, 61%                 WMD = -1.77                   -2.18, -1.35     \<0.01
  Hospital stay (d)          11                      309               339                                       0.006, 60%                WMD = -2.87                   -3.54, -2.21     \<0.01
  Overall complications      12                      341               345                                       0.74, 0%                  RR = 0.49                     0.30, 0.81       \<0.01
  Tumor size (cm)            13                      371               377                                       0.23, 21%                 WMD = -0.57                   -0.86, -0.29     \<0.01
  Recurrence                 8                       248               232                                       0.81, 0%                  RR = 0.66                     0.31, 1.42       0.29

CI, confidence interval; LAP, laparoscopic surgery; OPEN, open surgery; RR, risk ratio; WMD, weighted mean difference.

Publication bias
----------------

To test for publication bias, we used funnel plots and performed an Egger's test based on the incidence of overall postoperative complications (Figure [10](#F10){ref-type="fig"}). The graphical funnel plot showed that none of the studies lay outside the 95% CI boundaries, and there was no evidence of publication bias.

![Funnel plot of the overall postoperative complications.](1477-7819-12-206-10){#F10}

Discussion
==========

GISTs, although rare, are the most common mesenchymal tumors arising in the wall of the gastrointestinal tract. Surgery remains the mainstay of definitive therapy for non-metastatic GISTs. Recent evidence suggests that prognosis is mainly based on tumor size and histological features rather than wide resection margins \[[@B3],[@B42]\], which makes laparoscopic resection more popular for GIST treatment. Recently, some meta-analysises showed the superiority of LAP to OPEN \[[@B43],[@B44]\]. With the development of the laparoscopic technique, several additional articles that compare LAP with OPEN have been published since that analysis \[[@B36]-[@B41]\]. Therefore, we performed this updated meta-analysis to broaden the current knowledge on the clinical value of LAP.

We failed to include randomized controlled trials (RCTs) in this study. Although RCTs are first choice for a high-quality of meta-analysis, there are some hurdles to overcome such as learning curve effects, ethical issues, and the relatively low incidence of GISTs during the conduction of a high-quality RCT to evaluate this new surgical approach. Therefore, we made a number of efforts to ensure convincing results from non-RCTs, including the use of NOS to assess the quality of the studies and exclude low-quality studies; conducting subgroup analysis for studies of wedge resection, comparable tumor size or risk index to minimize the selection bias; and using funnel plots and Egger's test to detect publication bias.

Our pooled analysis demonstrated faster gastrointestinal recovery in LAP. Reduced use of analgesic drugs, milder acute inflammatory response, and earlier postoperative activities are considered to be the main reasons for earlier gastrointestinal recovery in this type of surgery. The meta-analysis demonstrated a reduced number of complications in the LAP versus OPEN group, which may have resulted from a reduction in systematic complications. It is conceivable that surgical complications were similar between groups because LAP, though less invasive, results in the same resection extent as OPEN. Decreased pulmonary infection, which is the most common systemic complication, could explain the reduced systemic complications in LAP. Pain after surgery was less serious in LAP than in OPEN, reflected by a shorter duration or lower dosage of analgesics. The pain caused by the large incision as well as the use of tension sutures and abdominal bandages after laparotomy would deter patients' attempts to cough, expectorate and perform breathing exercise effectively, resulting in complications such as pulmonary infection \[[@B45]\]. Our study demonstrated the postoperative hospital stay was 3.6 days shorter for LAP patients, which reasonably results from faster gastrointestinal recovery and a reduced number of complications in LAP.

The present analysis demonstrated that the operative time in the LAP group was similar to OPEN, which is in contrast to many other types of gastrointestinal surgery \[[@B46]-[@B49]\]. This result was mainly based on two factors. Lymphadenectomy, which is complicated and time-consuming under laparoscopy, is not generally required in LAP. Time spent on the establishment of pneumoperitoneum and the closure of the trocar incision and mini-laparotomy is likely to be shorter than the opening and closing of a laparotomy. Additionally, most studies involving less operative time in the LAP group had a relatively larger sample size or were recently published \[[@B29],[@B33]-[@B41]\], which might explain why the LAP appeared to be shorter than OPEN because of an accumulation of laparoscopic skills and the development of laparoscopic instruments.

Operative blood loss was shown in the pooled analysis to be lower in LAP. The reduced length of incision and the application of energy-dividing devices contribute to this reduction in blood loss. Moreover, the magnified view of laparoscopy allows for meticulous manipulation and reduction of injury. In our study, the asymmetric distribution of tumor size or extent of resection makes comparison of operative blood loss inherently flawed and at a high risk for confounding factors. So a subgroup analysis for studies with comparable tumor size or extent of resection was conducted, and less operative blood loss was still observed, which suggests that the technique of LAP itself might be the main reason for less operative blood loss.

Long-term survival remains critical for patients with GIST because of its malignant potential. Our study confirmed the safety of LAP for GISTs compared with OPEN. The postoperative recurrence in the LAP group was less than that of the OPEN group with statistical significance. However, the observed advantages of laparoscopy may be skewed by selection bias regarding tumor size. In several included studies, larger tumor size and higher risk classification were dominant in the OPEN group. According to the risk assessment classification \[[@B3]\], tumor size and mitotic index are two key factors on GISTs long-term outcomes. Thus, the studies with the same surgical approach (wedge resection) as well as those with comparable tumor size or risk classification were included in a subgroup analysis. The results of two subgroup analyses showed that the risk of postoperative recurrence in the LAP group was similar to the OPEN group. The increased experience of laparoscopic procedures, no touch of tumor and retrieving the tumor with an endobag \[[@B8],[@B36]\] may have contributed to this result. In addition, we also observed that the common sites of postoperative recurrence of GISTs included liver metastasis, peritoneal metastasis and local recurrence. Most cases of recurrence or metastasis had a trend toward higher-risk profiles and no port metastasis was identified, which suggests tumor recurrence is not clearly related to the surgical approach \[[@B21],[@B22],[@B24],[@B26],[@B27],[@B29],[@B31],[@B36],[@B39]\].

There are several limitations to our studies that must be taken into account when considering the results. First, all of the studies included in this meta-analysis are non-RCTs, which could lead to substantial selection and observation bias. Second, despite the majority of studies analyzed focusing only on GISTs, some included studies had several cases of other types of gastric submucosal tumors, such as neurilemmomas and leiomyomas. Because the sample size of remaining studies was still small for definitive conclusions on the safety and effectiveness of LAP, we did not exclude the study. Although such a low number does not imply a significant bias, it still can lead to clinical heterogeneity. Third, although the funnel plot showed that publication bias is unlikely, clinicians must be aware of possible publication bias when using evidence in clinical practice. Also, the follow-up duration of cases in the meta-analysis is too short for the low-risk GISTs to have developed tumor recurrence, which may have an influence on the tumor recurrence rate, and more long-term follow-up studies are awaited.

Conclusions
===========

The current clinical evidence revealed that LAP is safe and feasible for the treatment of gastric GISTs in regards to short- and long-term outcomes. In selective patients, LAP is preferable compared with OPEN for its minimally invasive advantages. More well-designed RCTs or prospective cohort studies are awaited to adequately evaluate the status of laparoscopic resection for gastric GISTs.
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